2. Search Result
Search Result
Pathways Recommended: Anti-infection
Results for "

infection models

" in MedChemExpress (MCE) Product Catalog:

256

Inhibitors & Agonists

1

Screening Libraries

2

Fluorescent Dyes

4

Biochemical Assay Reagents

22

Peptides

3

Inhibitory Antibodies

24

Natural
Products

10

Isotope-Labeled Compounds

1

Click Chemistry

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-145586
    Onradivir

    ZSP1273

    		 Influenza Virus DNA/RNA Synthesis Infection
    Onradivir (ZSP1273) is an orally active antiviral agent targeting influenza A virus RNA polymerase PB2 subunit with an IC50 of 0.562 nM. Onradivir inhibits cap binding to influenza A virus RNA polymerase PB2 subunit, suppresses viral replication, reduces viral titres and RNA loads, and inhibits influenza A virus infection. Onradivir maintains high survival rates in influenza A virus-infected mice, and reduces influenza A virus titers in a murine model. Onradivir can be used for the research of influenza A virus infection .
    Onradivir
  • HY-B0027
    Valnemulin hydrochloride
    2 Publications Verification

    		 Antibiotic Bacterial Infection Metabolic Disease
    Valnemulin hydrochloride is an orally effective truncated pleurotin antibiotic that inhibits protein synthesis in bacteria by binding to peptidyl transferase in the 50s ribosome subunit. Valnemulin hydrochloride effectively eliminates Mycobacterium bovis in the lungs in an experimental bovine model of Mycoplasma bovis infection. Valnemulin hydrochloride can reduce the mortality of epidemic rabbit enteropathy and has no adverse effect on the growth performance of rabbits .
    Valnemulin hydrochloride
  • HY-17035
    Doramectin
    5 Publications Verification

    		 Parasite Antibiotic Bacterial Infection
    Doramectin is a derivative of Ivermectin (HY-15310). Doramectin is a potent antiparasitic antibiotic. Doramectin is an active compound against S.mansoni in an NMRI mouse infection model .
    Doramectin
  • HY-137048
    PF-00835231
    4 Publications Verification

    		 SARS-CoV HIV HCV Infection
    PF-00835231 is a CoV-2 cysteine 3C-like protease (3CL pro) inhibitor, with IC50s of 0.27 nM and 4 nM for SARS CoV-2 and SARS CoV-1 3CL pro, respectively. PF-00835231 is developed for the research of anti-SARS-CoV-2/COVID-19. PF-00835231 can inhibit cell infections and also suppress infections in animal models .
    PF-00835231
  • HY-146331
    PC190723

    		Bacterial Infection
    PC190723 is a bacterial cell division protein FtsZ inhibitor (IC50 = 55 nM). PC 190723 prevents cell division. PC190723 has potent and selective bactericidal activity against staphylococci, including methicillin- and multi-drug-resistant Staphylococcus aureus. PC190723 induces nucleated assembly of Bs-FtsZ into single-stranded coiled protofilaments and polymorphic condensates. PC190723 can be studied in anti-bacterial infection research .
    PC190723
  • HY-107830
    Methyl cholate

    		Endogenous Metabolite Collagen Infection Metabolic Disease
    Methyl cholate is a bile acid analog and a specific inhibitor of TcdB toxin from Clostridioides difficile. Methyl cholate exerts a stronger selective inhibitory effect on TcdB than on TcdA. Methyl cholate induces conformational stabilization by binding to a unique site of TcdB, thereby blocking the binding of the toxin to host receptors and its self-processing process. Methyl cholate effectively protects human fibroblasts from TcdB-induced cytopathic effects. Methyl cholate exhibits dose-dependent anti-hepatic fibrosis activity in both cellular and zebrafish models, and significantly reduces the expression levels of α-SMA and COL-I. Methyl cholate is suitable for in-depth research in the fields of Clostridioides difficile infection and hepatic fibrosis .
    Methyl cholate
  • HY-103363
    SB-328437
    3 Publications Verification

    		 CCR Thymidylate Synthase Inflammation/Immunology Cancer
    SB-328437 is a potent, selective non-peptide CCR3 antagonist with an IC50 of 4.5 nM. SB-328437 can inhibit eosinophil migration induced by eotaxin, eotaxin-2, and monocyte chemotactic protein-4. In addition, SB-328437 can sensitize 5-FU (HY-90006)-resistant gastric cancer cells. SB-328437 can also reduce the recruitment of neutrophils to the lungs and pulmonary inflammation during acute inflammation. SB-328437 can be used in the research of inflammation-related diseases .
    SB-328437
  • HY-P99604
    Cilgavimab

    AZD-1061; COV2-2130

    		 SARS-CoV Infection
    Cilgavimab (AZD-1061; COV2-2130) is a human SARS-CoV-2-neutralizing monoclonal antibody, can compose monoclonal-antibody combination AZD7442 with Tixagevimab (HY-P99556). Cilgavimab shows protective action on mouse models of SARS-CoV-2 infection .
    Cilgavimab
  • HY-W025784
    Kalibor

    Sodium tetraphenylborate; Tetraphenylboron sodium

    		 Bacterial Infection
    Kalibor (Sodium tetraphenylborate; Tetraphenylboron sodium) is a boron-based salt and antibacterial agent. Kalibor exerts activity against Neisseria meningitidis and Neisseria gonorrhoeae. Kalibor facilitates boron uptake by Neisseria meningitidis cells. Kalibor reduces bacterial burden in a mouse model of Neisseria meningitidis bacteremia. Kalibor can be used for the research of bacterial infection, such as meningococcal bacteremia .
    Kalibor
  • HY-B1864A
    Kasugamycin hydrochloride
    1 Publications Verification

    Ksg hydrochloride

    		 Environmental Pollutants Antibiotic Bacterial Infection
    Kasugamycin (Ksg) hydrochloride hydrate is an antibiotic that binds to 30s and 70s ribosomes but not to the 50s subunit, and has anti-infective activity. Kasugamycin hydrochloride hydrate mimics mRNA nucleotides, disrupts tRNA binding and inhibits canonical translation initiation. Kasugamycin hydrochloride hydrate increases the sensitivity of mycobacteria to Rifampicin (HY-B0272) in vitro and in mouse infection models .
    Kasugamycin hydrochloride
  • HY-N1136
    (+)-Totarol

    		Bacterial Infection
    (+)-Totarol is a diterpenoid membrane-disrupting agent and membrane structure regulator found in plants of the genus Podocarpus spp. (+)-Totarol inserts into phospholipid model membranes, disrupts phospholipid packing, and impairs the functional integrity of membranes. (+)-Totarol exhibits antibacterial activity against a variety of bacterial species and β-lactam-resistant strains, and its action is associated with changes in membrane physical properties. (+)-Totarol can be used in studies related to bacterial infections .
    (+)-Totarol
  • HY-W041988
    Fmoc-Glu-OMe

    		Bacterial Infection
    Fmoc-Glu-OMe is a glutamic acid derivative. Fmoc-Glu-OMe exhibits significant antibacterial activity and excellent gelation properties in silver nitrate (AgNO3) solution. Fmoc-Glu-OMe promotes wound healing in rat models and eliminates bacteria in MRSA-infected rat wound models. Fmoc-Glu-OMe can be used in studies related to wound infections and MRSA-infected wounds .
    Fmoc-Glu-OMe
  • HY-139602
    (+)-JNJ-A07
    2 Publications Verification

    		 Flavivirus Dengue Virus Virus Protease Infection
    (+)-JNJ-A07 is a highly potent, orally active pan-serotype dengue virus inhibitor targeting the NS3-NS4B interaction. (+)-JNJ-A07 exerts nanomolar to picomolar activity against a panel of 21 clinical isolates. (+)-JNJ-A07 has a favourable pharmacokinetic profile that results in outstanding efficacy against dengue virus infection in mouse infection models .
    (+)-JNJ-A07
  • HY-P2460
    SMAP-29

    		Bacterial Fungal Interleukin Related TNF Receptor Infection Inflammation/Immunology
    SMAP‑29 is a cathelicidin antimicrobial peptide with LPS‑binding and anti‑inflammatory properties. SMAP‑29 exerts broad‑spectrum antimicrobial activity against bacteria, fungi and multidrug‑resistant isolates. SMAP‑29 kills pathogens by permeabilizing bacterial membranes, inducing depolarization and cell lysis, and also inhibits inflammatory cytokines while reducing lethality in septic shock and pneumonia models. SMAP-29 can be used for research on bacterial infections, drug-resistant infections, septic shock .
    SMAP-29
  • HY-109195
    Vebicorvir
    2 Publications Verification

    ABI-H0731

    		 HBV Infection Inflammation/Immunology
    Vebicorvir (ABI-H0731) is a first-generation hepatitis B virus (HBV) core protein inhibitor. Vebicorvir (ABI-H0731) suppresses covalently closed circular DNA (cccDNA) formation in two de novo infection models with EC50s from 1.84 μM to 7.3 μM .
    Vebicorvir
  • HY-B1864B
    Kasugamycin hydrochloride hydrate
    1 Publications Verification

    Ksg hydrochloride hydrate

    		 Antibiotic Bacterial Infection
    Kasugamycin (Ksg) hydrochloride hydrate is an antibiotic that binds to 30s and 70s ribosomes but not to the 50s subunit, and has anti-infective activity. Kasugamycin hydrochloride hydrate mimics mRNA nucleotides, disrupts tRNA binding and inhibits canonical translation initiation. Kasugamycin hydrochloride hydrate increases the sensitivity of mycobacteria to Rifampicin (HY-B0272) in vitro and in mouse infection models .
    Kasugamycin hydrochloride hydrate
  • HY-157536
    SMT-738

    		Bacterial Infection Inflammation/Immunology
    SMT-738 is a bacterial bactericide. SMT-738 targets the small molecules responsible for lipoprotein transport in Enterobacteriaceae, causing abnormal lipoprotein localization and bacterial cell death. SMT-738 inhibits the growth of E. coli and K. pneumoniae. SMT-738 reduces bacterial loads in mouse models of urinary tract infection, bloodstream infection, and pulmonary infection caused by Enterobacterales. SMT-738 can be used in the research of Enterobacteriaceae infections, urinary tract infections, bloodstream infections, and pneumonia .
    SMT-738
  • HY-139398
    TBI-223
    1 Publications Verification

    		 Antibiotic Bacterial Infection
    TBI-223 is an orally active oxazolidinone antibiotic and an antimicrobial. TBI-223 shows activity against Mycobacterium tuberculosis (Mtb). TBI-223 exhibits an IC50 of 68 μg/mL for inhibiting mitochondrial protein synthesis (MPS) in HepG2 cells. TBI-223 is effective in three mouse models (bloodstream infection, skin infection, and bone infection) of methicillin-resistant staphylococcus aureus infection. TBI-223 can be used for the study of tuberculosis .
    TBI-223
  • HY-P10056
    HEP-1

    Human ezrin peptide (324-337)

    		 HIV HCV HPV Influenza Virus Interleukin Related Infection Inflammation/Immunology
    HEP-1 (Human ezrin peptide (324 - 337)) is an orally active peptide with antiviral, anti-inflammatory, and immunomodulatory activities. HEP-1 is effective against infections by various viruses such as HIV, HCV, herpes viruses, HPV, and influenza viruses. As an immunomodulator, HEP-1 can enhance the adaptive immunity mediated by B cells and T cells. HEP-1 can also increase the antibody titers after hepatitis B vaccination. HEP-1 can be used in the research of viral infections and inflammation-related diseases .
    HEP-1
  • HY-W250152
    Polycytidylic acid potassium

    		Biochemical Assay Reagents Inflammation/Immunology
    Polycytidylic acid potassium is an immunostimulant and synthetic double-stranded RNA. Polycytidylic acid potassium can be used experimentally to model viral infections in vivo. Polycytidylic acid potassium is a common tool in immune system research .
    Polycytidylic acid potassium
  • HY-17035R
    Doramectin (Standard)

    		Reference Standards Parasite Antibiotic Bacterial Infection
    Doramectin (Standard) is the analytical standard of Doramectin. This product is intended for research and analytical applications. Doramectin is a derivative of Ivermectin (HY-15310). Doramectin is a potent antiparasitic antibiotic. Doramectin is an active compound against S.mansoni in an NMRI mouse infection model .
    Doramectin (Standard)
  • HY-P3350
    LS-BF1

    		Bacterial Infection
    LS-BF1 is a stable and low toxic cationic antimicrobial peptide. LS-BF1 displays broad spectrum of antibacterial activity, including the challenging ESKAPE pathogens, by cell membrane disruptive mechanism. LS-BF1 shows good in vivo efficacy for elimination of bacteria in a mouse infection model[1].
    LS-BF1
  • HY-N7934
    Trachelogenin

    (-)-Trachelogenin

    		 HCV Infection Neurological Disease Inflammation/Immunology
    Trachelogenin ((-)-Trachelogenin) is an HCV entry inhibitor without genotype specificity, and with low cytotoxicity. Trachelogenin inhibits HCVcc infection and HCVpp cell entry in a dose-dependent manner with an IC50 of 0.325 and 0.259 μg/mL in HCVcc and HCVpp models, respectively. Trachelogenin exhibits effective antiviral, anti-inflammatory and analgesic effects .
    Trachelogenin
  • HY-147015
    HOE961

    		Orthopoxvirus Infection
    HOE961, the diacetate ester proagent of S2242, is active against respiratory cowpox virus infections, is orally active in infection models. Anti-orthopoxvirus activity .
    HOE961
  • HY-172456
    JSF-4898

    		Bacterial Infection
    JSF-4898 is an orally active inhibitor of the MenG enzyme in Mycobacterium tuberculosis. JSF-4898 has MIC of 0.78 μM against Mycobacterium tuberculosis H37Rv. JSF-4898 can enhance the efficacy of Rifampicin (HY-B0272) in a subacute model of Mycobacterium tuberculosis infection in mice .
    JSF-4898
  • HY-172349
    JNJ-2901

    		Bacterial Infection
    JNJ-2901 is an inhibitor of M. tuberculosis cytochrome bc1:aa3. JNJ-2901 reduces bacterial load in the acute/chronic mouse infection models of M. tuberculosis H37Rv-ΔcydAB. JNJ-2901 can be used in tuberculosis (TB) research .
    JNJ-2901
  • HY-171956
    Carmaphycin-17

    		Proteasome Parasite Infection
    Carmaphycin-17 (CP-17) is a selective 20S proteasome inhibitor with an EC50 of 217 ?nM. Carmaphycin-17 has potent antimicrobial activity against Trichomonas vaginalis. Carmaphycin-17 overcomes Metronidazole (HY-B0318) resistance and significantly reduces parasite burden upon topical treatment without any apparent adverse effects in vaginal trichomonad infection mice model. Carmaphycin-17 can be used for sexually transmitted disease like trichomoniasis research .
    Carmaphycin-17
  • HY-P11004
    A3-APO

    		Bacterial Antibiotic Infection
    A3-APO is an antimicrobial peptide. A3-APO has a significant antimicrobial activity by a dual mode of action with both membrane disintegration and intracellular target inhibition. A3-APO can deactivate bacterial toxins and increase the expression of anti-inflammatory cytokines (such as IL-4 and IL-10), without antimicrobial resistance. A3-APO accelerates burn wounds healing in mice infection model of Acinetobacter baumannii and Staphylococcus aureus .
    A3-APO
  • HY-117951
    ANT431

    		Beta-lactamase Infection
    ANT431 is a metallo-β-lactamase inhibitor that also restores the effectiveness of Meropenem (HY-13678) in a mouse thigh Escherichia coli infection model .
    ANT431
  • HY-175461
    AVI-4206

    		SARS-CoV Infection
    AVI-4206 is a selective Mac1 inhibitor with an lC50 of 64 nM. AVI-4206 reduces viral replication, restores an interferon response, and leads to a survival benefit in an animal model of SARS-CoV-2 infection. AVI-4206 can be used the study of SARS-CoV-2 infection .
    AVI-4206
  • HY-162144
    BDM91288

    		Bacterial Infection
    BDM91288 is an orally active AcrB efflux pump inhibitor of pyridinium piperazine. BDM91288 can enhance the in vivo efficacy of levofloxacin (HY-B0330) in the treatment of Klebsiella pneumoniae pulmonary infection in mouse models .
    BDM91288
  • HY-P991655
    AGS-009

    		IFNAR HIV Infection Inflammation/Immunology
    AGS-009 is a humanized monoclonal neutralising antibody targeting IFN-α. AGS-009 significantly reduces activated lymphocytes, such as CD4 + and CD8 + T cells as well as B cells in SIV infection rhesus macaque models. AGS-009 can be used for autoimmune diseases like systemic lupus erythematosus (SLE) and HIV infections research .
    AGS-009
  • HY-163181
    MSU-43085

    		Bacterial Infection
    MSU-43085 is an orally active MmpL3 inhibitor of Mycobacterium tuberculosis (Mtb). MSU-43085 effectively inhibits Mtb in an acute murine tuberculosis infection model. MSU-43085 can be used in tuberculosis research .
    MSU-43085
  • HY-118338
    WRR-483

    		Parasite Infection
    WRR-483 is an analog of K11777, an inhibitor of cruzain, used to inhibit the proliferation of Trypanosoma cruzi in cell culture. WRR-483 can eradicate parasitic infection in an acute Chagas disease mouse model. WRR-483 is an irreversible cysteine protease inhibitor that shows pH-dependent high affinity and potent trypanocidal activity against cruzain and T. cruzi infection, and is expected to inhibit Chagas disease.
    WRR-483
  • HY-147014
    Cyclic HPMPC

    		CMV Orthopoxvirus Infection
    Cyclic HPMPC is a potent antiviral agent. Cyclic HPMPC can increase arterial oxygen saturation levels in lethal vaccinia virus (IHD strain)-infected mice. Cyclic HPMPC improves the outcome of congenital guinea pig cytomegalovirus (GPCMV) infection and decreases viral replication in guinea pig model .
    Cyclic HPMPC
  • HY-146079
    Antifungal agent 31

    		Fungal Infection
    Antifungal agent 31 (compound 12) is a potent and orally active triazole antifungal agents with a pyrrolotriazinone scaffold. Antifungal agent 31 shows antifungal activity against Candida spp. and filamentous fungi. Antifungal agent 31 significantly reduced mortality rates and kidney fungal burden in two murine models of lethal systemic infections .
    Antifungal agent 31
  • HY-145586A
    Onradivir monohydrate

    ZSP1273 monohydrate

    		 Influenza Virus DNA/RNA Synthesis Infection
    Onradivir (ZSP1273) monohydrate is an orally active antiviral agent targeting influenza A virus RNA polymerase PB2 subunit with an IC50 of 0.562 nM. Onradivir monohydrate inhibits cap binding to influenza A virus RNA polymerase PB2 subunit, suppresses viral replication, reduces viral titres and RNA loads, and inhibits influenza A virus infection. Onradivir monohydrate maintains high survival rates in influenza A virus-infected mice, and reduces influenza A virus titers in a murine model. Onradivir monohydrate can be used for the research of influenza A virus infection .
    Onradivir monohydrate
  • HY-175029
    ALG-097558

    		SARS-CoV Virus Protease Infection
    ALG-097558 is an orally active 3CLpro inhibitor. ALG-097558 demonstrates pan-coronavirus activity against various SARS-CoV-2 variants as well as other human coronaviruses (HCoVs) such as SARS-CoV-1, α-HCoV 229E, and β-HCoV OC43. ALG-097558 demonstrates potent inhibition with IC50s of 2 nM (SARS-CoV-2 3CLpro) and 6 nM (229E 3CLpro). ALG-097558 demonstrates antiviral activity in the SARS-CoV-2 hamster infection model. ALG-097558 can be used for the study of viral infections[1].
    ALG-097558
  • HY-178504
    Lug-15

    		Bacterial Infection
    Lug-15 is a rapid bactericidal agent. Lug-15 exhibits strong antibacterial activity against both Gram-positive and Gram-negative bacteria, including drug-resistant strains. Lug-15 rapidly kills bacteria primarily through membrane disruption and had a very low propensity to induce bacterial resistance. Lug-15 demonstrates low hemolytic toxicity and significant therapeutic potential in various infection models. Lug-15 can be used for research on combating infections caused by multi-drug resistant bacteria .
    Lug-15
  • HY-172264
    XT17

    		Antibiotic Bacterial DNA/RNA Synthesis Infection
    XT17 is an anthrone compound with broad-spectrum antibacterial activity. It exerts its antibacterial effect by disrupting the cell wall and inhibiting DNA synthesis. XT17 exhibits weak hemolytic activity, low cytotoxicity against mammalian cell lines, and a low frequency of drug resistance. Meanwhile, XT17 shows in vivo efficacy in a mouse corneal infection model induced by Staphylococcus aureus or Pseudomonas aeruginosa. Further docking studies have confirmed that XT17 can form a stable complex with bacterial gyrase. XT17 can be used in the research of the anti - infection field .
    XT17
  • HY-156122
    DHFR-IN-8

    		Dihydrofolate reductase (DHFR) Bacterial Infection
    DHFR-IN-8 (compound 6r) is a dihydrofolate reductase (DHFR) inhibitor that affects purine and thymidylate biosynthesis in cell proliferation and growth. DHFR-IN-8 inhibits methicillin-resistant Staphylococcus aureus (MRSA) ATCC 43300 (IC50=15.6 ng/mL) in mouse models of systemic infection and thigh infection .
    DHFR-IN-8
  • HY-162818
    Antibacterial agent 237

    		Bacterial Reactive Oxygen Species (ROS) Infection
    Antibacterial agent 237 (compound Ru-8) is a bacteriostatic agent for Staphylococcus aureus, with MIC of 0.78-1.56 μg/mL. Antibacterial agent 237 destroys bacterial cell membranes, changes their permeability, and induces bacteria to produce Reactive Oxygen Species, leading to bacterial death without causing drug resistance. Antibacterial agent 237 has low hemolytic toxicity to rabbit red blood cells and Raw 264.7 cells, and has significant antibacterial effects against Staphylococcus aureus in mouse skin wound infection models and Bacillus major larvae infection models .
    Antibacterial agent 237
  • HY-156123
    DHFR-IN-9

    		Dihydrofolate reductase (DHFR) Bacterial Infection Cancer
    DHFR-IN-9 (compound 8A) is a dihydrofolate reductase (DHFR) inhibitor that affects purine and thymidylate biosynthesis in cell proliferation and growth. DHFR-IN-9 inhibits methicillin-resistant Staphylococcus aureus (MRSA) ATCC 43300 (IC50=0.25 μg/mL) and has anti-infective effects in mouse models of systemic infection and thigh infection caused by it (dose: 2.5 mg /kg, 5 mg/kg; ip). DHFR-IN-9 has stronger anticancer activity than paclitaxel (Y-B0015) in a mouse model of breast cancer (dose: 2.5 mg/kg; ip; once every 3 days) .
    DHFR-IN-9
  • HY-176793
    JAK1-IN-18

    		JAK Infection Inflammation/Immunology Cancer
    JAK1-IN-18 (Example 2) is a selective JAK1 inhibitor with an IC50 of 0.15  nM for JAK1 over JAK2 and JAK3. JAK1-IN-18 significantly reduces inflammation in DSS (HY-116282C)-induced ulcerative colitis (UC) mouse models and DNBS(HY-W324435)-induced Crohn's disease (CD) rat models. JAK1-IN-18 can be used for autoimmune diseases (such as inflammatory bowel disease), viral infections (such as HBV infection) and cancers (such as blood cancer) research .
    JAK1-IN-18
  • HY-175254
    Antibiofilm agent-17

    		Bacterial Infection
    Antibiofilm agent-17 is a dual-action biofilm inhibitor against Pseudomonas aeruginosa (IC50 = 0.33 μM). Antibiofilm agent-17 inhibits biofilm growth by reducing quorum sensing-mediated virulence production and iron ion acquisition. Antibiofilm agent-17 exhibits synergistic antimicrobial effects in a mouse wound infection model. Antibiofilm agent-17 can be used in research on combating Pseudomonas aeruginosa infections .
    Antibiofilm agent-17
  • HY-174985
    Anti-MRSA agent 32

    		Bacterial Infection
    Anti-MRSA agent 32 (Compound 26) is an orally active and selective SaClpP (Staphylococcus aureus ClpP protease) activator with an EC50 value of 0.98 μM. Anti-MRSA agent 32 activates SaClpP to abnormally degrade bacterial proteins, inhibiting the proliferation of Staphylococcus aureus. Anti-MRSA agent 32 promotes wound healing in a murine skin infection model. Anti-MRSA agent 32 is promising for research of infectious diseases such as methicillin-resistant Staphylococcus aureus (MRSA) infections .
    Anti-MRSA agent 32
  • HY-173270
    Antibacterial synergist 3

    		Bacterial Infection
    Antibacterial synergist 3 is a dual-acting inhibitor of biofilm (IC50 of PAO1: 0.40 μM and IC50 of PA14: 1.45 μM). Antibacterial synergist 3 reduces virulence production by inhibiting the quorum sensing (QS) system and induces iron deficiency in P. aeruginosa PAO1. Antibacterial synergist 3 enhances the efficacy of Tobramycin (HY-B0441) and Ciprofloxacin (HY-B0356) in a mouse wound infection model. Antibacterial synergist 3 can be used for the research of P. aeruginosa infections .
    Antibacterial synergist 3
  • HY-P11037
    soVIRIP

    		HIV Infection
    soVIRIP is a virus inhibitory peptide with an IC50 of 1.2  μM for HIV-1 . soVIRIP binds to the HIV-1 GP41 fusion peptide and inhibits viral fusion and entry into host cells. soVIRIP has broad-spectrum anti-HIV-1 activities with nontoxicity in zebrafish models. soVIRIP can used for viral infections research .
    soVIRIP
  • HY-173472
    MBL-IN-5

    		Bacterial Beta-lactamase Infection
    MBL-IN-5 is a metallo-β-lactamase (MBL) inhibitor. MBL-IN-5 inhibits three clinically relevant B1 subfamily MBLs (NDM-1, VIM-1, and IMP-1) with IC50s of 0.05  nM, 14  nM and 21 nM respectively. MBL-IN-5 remarkably enhances carbapenems’ effectiveness against MBL-producing clinical strains and significantly reduces the bacterial load in a neutropenic murine thigh infection model combined with the IPM antibiotic .
    MBL-IN-5
  • HY-111047
    GSK945237

    		Topoisomerase Bacterial Infection
    GSK945237 is a potent and orally active bacterial type IIA topoisomerases inhibitor. GSK945237 shows broad-spectrum activity against Gram-positive and Gram-negative bacteria (IC50 of 0.034 μg/mL against H. influenzae DNA gyrase). GSK945237 demonstrates good in vivo efficacy in a rat respiratory tract infection model. GSK945237 can be used for anti-infection research .
    GSK945237

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: